Rosenblatt Reiterates Sell on CME Gr, Maintains $173 Price Target
Portfolio Pulse from Benzinga Newsdesk
Rosenblatt analyst Andrew Bond has reiterated a 'Sell' rating on CME Group (NASDAQ:CME) and maintained a price target of $173.
October 04, 2023 | 11:54 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rosenblatt analyst Andrew Bond has reiterated a 'Sell' rating on CME Group, maintaining a price target of $173.
The 'Sell' rating from Rosenblatt analyst Andrew Bond indicates a negative outlook for CME Group. The maintained price target of $173 suggests that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100